IJERPH, Vol. 18, Pages 12636: & beta;-Glucans Could Be Adjuvants for SARS-CoV-2 Virus Vaccines (COVID-19)

IJERPH, Vol. 18, Pages 12636: β-Glucans Could Be Adjuvants for SARS-CoV-2 Virus Vaccines (COVID-19) International Journal of Environmental Research and Public Health doi: 10.3390/ijerph182312636 Authors: Alfredo Córdova-Martínez Alberto Caballero-García Enrique Roche David C. Noriega Waiting for an effective treatment against the SARS-CoV-2 virus (the cause of COVID-19), the current alternatives include prevention and the use of vaccines. At the moment, vaccination is the most effective strategy in the fight against pandemic. Vaccines can be administered with different natural biological products (adjuvants) with immunomodulating properties. Adjuvants can be taken orally, complementing vaccine action. Adjuvant compounds could play a key role in alleviating the symptoms of the disease, as well as in enhancing vaccine action. Adjuvants also contribute to an effective immune response and can enhance the protective effect of vaccines in immunocompromised individuals such as the elderly. Adjuvants must not produce adverse effects, toxicity, or any other symptoms that could alter immune system function. Vaccine adjuvants are substances of wide varying chemical structure that are used to boost the immune response against a simultaneously administered antigen. Glucans could work as adjuvants due to their immunomodulatory biological activity. In this respect, β-(1,3)-(1,6) glucans are considered the most effective and safe according to the list i...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research